-
Several studies have suggested that procalcitonin may be a useful biochemical marker to differentiate sepsis from other, non-infectious, causes of the systemic inflammatory response syndrome (SIRS), such as pancreatitis.
-
Systemic and pulmonary inflammation are key in the development and progression of the acute respiratory distress syndrome (ARDS). Lack of improvements in inflammatory markers and in the lung injury score (LIS) by day 7 are associated with higher mortality.
-
Van den Berghe et al have recently reported the results of intensive insulin therapy (IIT) on morbidity and mortality in medical intensive care unit patients.
-
Gonococcal Infections, CDC's Updated Treatment; Head Lice Malathion First-Line Treatment; Statins, May Cut the Risk of Cataracts; FDA Actions
-
-
-
A simple questionnaire can identify individuals at risk for chronic kidney disease.
-
A new class of drug has been approved for the treatment of cutaneous T-cell lymphoma (CTCL) such as mycosis fungoides.
-
Persons who do not suffer hyperhidrosis (HID) may be surprised to learn that it has been associated with both occupational and physical impairment, as well as limitations in social interaction.
-
Torcetrapib, a cholesteryl ester transfer protein (CETP) inhibitor, has been in development by Pfizer for nearly 15 years.
